Literature DB >> 2422524

Analysis of methotrexate polyglutamate derivatives in vivo.

B A Kamen, N Winick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2422524     DOI： 10.1016/0076-6879(86)22191-6

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN： 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  9 in total

1.  Hepatic methotrexate content and progression of hepatic fibrosis: preliminary findings.

Authors:  M J Ahern; S Kevat; W Hill; P J Hayball; H Harley; P D Hall
Journal:  Ann Rheum Dis       Date:  1991-07       Impact factor: 19.103

2.  Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.

Authors:  Peter D Cole; Richard A Drachtman; Angela K Smith; Sarah Cate; Richard A Larson; Douglas S Hawkins; John Holcenberg; Kara Kelly; Barton A Kamen
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

3.  Methotrexate (MTX) concentration in tumors following low-dose MTX.

Authors:  N J Winick; B A Kamen; A Streckfuss; J Craig; F McGuirt; R L Capizzi; F Sklar; D Coln
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

4.  Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.

Authors:  Torben S Mikkelsen; Alex Sparreboom; Cheng Cheng; Yinmei Zhou; James M Boyett; Susana C Raimondi; John C Panetta; W Paul Bowman; John T Sandlund; Ching-Hon Pui; Mary V Relling; William E Evans
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

5.  Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.

Authors:  E Masson; M V Relling; T W Synold; Q Liu; J D Schuetz; J T Sandlund; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

6.  In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes.

Authors:  H Schrøder; K Fogh; T Herlin
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

7.  Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia.

Authors:  H Schrøder; K Fogh
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

8.  Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.

Authors:  Deborah French; Wenjian Yang; Cheng Cheng; Susana C Raimondi; Charles G Mullighan; James R Downing; William E Evans; Ching-Hon Pui; Mary V Relling
Journal:  Blood       Date:  2008-12-09       Impact factor: 22.113

9.  Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia.

Authors:  T W Synold; M V Relling; J M Boyett; G K Rivera; J T Sandlund; H Mahmoud; W M Crist; C H Pui; W E Evans
Journal:  J Clin Invest       Date:  1994-11       Impact factor: 14.808
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.